Market Overview

Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184

Related IDIX
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
UPDATE: Deutsche Bank Initiates Coverage On Merck
Merck Aims at Superbugs with $9.5B Cubist Buy (Fox Business)

Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.

Posted-In: News FDA Movers


Related Articles (IDIX)

Around the Web, We're Loving...

Get Benzinga's Newsletters